PRTG PORTAGE BIOTECH INC

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Ian Walters, M.D. to serve as expert panelist discussing the future of immune checkpoint inhibitors

WESTPORT, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced today that CEO Dr. Ian Walters will serve as an expert spokesperson on an oncology panel discussion at the upcoming BIO International Conference taking place in Boston, Massachusetts June 5-8, 2023.

Panel Date and Time: Thursday, June 8, 10:15 – 11:15 a.m. ET Session Room 254A

Title: Are We Past the Checkpoint?

Dr. Walters will be joined by industry experts during the panel to explore the future of the immune checkpoint inhibitor (ICI) space and the up-and-coming approaches to reactivating the body's own immune system. The panelists will discuss how the field of immuno-oncology has evolved, strategies to improve success in ICIs and entirely new approaches.

In addition to the panel, members of Portage’s management team will be in attendance to explore potential collaborations and partnerships with other industry leaders.

For more information on the panel and to register, visit the .

About Portage Biotech Inc.

Portage is a clinical-stage immuno-oncology company advancing multi-targeted therapies to extend survival and significantly improve the lives of patients with cancer. Lead programs in the Portage portfolio include first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. These programs are being advanced using innovative trial designs and translational data to identify the patient populations most likely to benefit from treatment. The Company’s unique business model leverages a strong network of academic experts and large pharma partners to rapidly and efficiently advance multiple products. For more information, please visit , follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations

Chuck Padala

Media Relations

Raena Mina, Ph.D.



EN
01/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PORTAGE BIOTECH INC

 PRESS RELEASE

AlphaTON Capital Releases Market Update on Outstanding Shares, Warrant...

AlphaTON Capital Releases Market Update on Outstanding Shares, Warrants, Options, and RSUs Road Town, Tortola, British Virgin Islands, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. () ("AlphaTON" or the "Company"), the world's leading public technology company scaling the Telegram super-app with an addressable market of one billion monthly active users, today announced a market update on its outstanding shares, warrants, options, and RSUs. As of February 19, 2026, the Company has outstanding: 23,434,588 ordinary shares 1,373,686 ordinary shares issuable upon the exercise of ou...

 PRESS RELEASE

Brittany Kaiser, CEO of AlphaTON Capital ($ATON), Goes Live on X to Re...

Brittany Kaiser, CEO of AlphaTON Capital ($ATON), Goes Live on X to Reveal the Strategy Behind Recent AI Infrastructure Play San Juan, Puerto Rico, USA, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Brittany Kaiser, whistleblower, data rights pioneer, and the CEO of AlphaTON Capital (NASDAQ: ATON), joins Mario Nawfal X Space for a live conversation on confidential AI access and why everyone needs to own their digital identity. For the first time, she will reveal the strategy behind AlphaTON's GPU acquisition playbook, the infrastructure powering Cocoon AI (Telegram’s AI), and why this Nasdaq list...

 PRESS RELEASE

AlphaTON Capital Executes Binding Call Option to Sell Legacy Biotech A...

AlphaTON Capital Executes Binding Call Option to Sell Legacy Biotech Asset iOx Therapeutics to Immunova Structure Preserves Shareholder Upside Through Equity, Milestones, Royalties, and Sublicensing Participation Dover, DE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. ( ("AlphaTON" or the "Company"), the world's leading public technology company scaling the Telegram super app for an addressable market of over 1 billion monthly active users, today announced the execution of a binding call option agreement with Immunova, LLC ("Immunova"), granting Immunova, or an affiliate, th...

 PRESS RELEASE

AlphaTON Capital Adds Deployment of 504 NVIDIA Blackwell B200 GPU Comp...

AlphaTON Capital Adds Deployment of 504 NVIDIA Blackwell B200 GPU Computers for AI Market Infrastructure This Additional Deployment Scales AlphaTON’s AI Revenue Toronto, Canada, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (), the world's leading public technology company scaling the Telegram super app with AI Infrastructure and Telegram Applications for its addressable market of 1 billion monthly active users, today reports the signing and closing of a strategic $30 million AI compute infrastructure lease agreement, adding 504 NVIDIA B200 chips to its deployment capacity in ...

 PRESS RELEASE

AlphaTON Capital dévoile son infrastructure d’IA confidentielle pour 1...

AlphaTON Capital dévoile son infrastructure d’IA confidentielle pour 1 milliard d’utilisateurs lors du Consensus Hong Kong La PDG, Brittany Kaiser, le conseiller stratégique, Anthony Scaramucci, et le président de la Midnight Foundation, Fahmi Syed, présenteront la position de pionnier d’AlphaTON dans le domaine de l’IA respectueuse de la vie privée à grande échelle HONG KONG, 12 févr. 2026 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (Nasdaq : ATON), leader mondial des sociétés technologiques cotées en bourse déployant la super-application Telegram sur un marché potentiel de plus d’un mi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch